AMR: ENABLE selects Mutabilis candidate
07 November 2019
A new oral combination treatment that might overcome beta-lactam / fluoroquinolone co-resistance has now been selected for accelerated preclinical development by the Portfolio Management Committee of ENABLE, a programme under the Innovative Medicines Initiative’s (IMI) New Drugs 4 Bad Bugs (ND4BB) portfolio.
Further reading: European Biotechnology
Author(s): tg
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
LifeArc |
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!